SCHEMBL5543968

SCHEMBL5543968

O=[C]OCCc1nnnn1-c1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.48
HTT P42858 3/20 0.44
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 5/20 0.42
MAPT P10636 1/20 0.40
HSD11B1 P28845 4/20 0.40
PKM P14618 1/20 0.38
NLRP3 Q96P20 1/20 0.38
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
CNKSR1 Q969H4 1/20 0.37
NOTUM Q6P988 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
TLR8 Q9NR97 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536565 0.86 HSD11B1 (0.44) POLBHTTLMNAALDH1A1MAPT
SCHEMBL5537088 0.86 ALDH1A1 (0.42) POLBHTTLMNAALDH1A1MAPT
SCHEMBL5543435 0.85 ALDH1A1 (0.48) HTTLMNAL3MBTL1ALDH1A1MAPT
SCHEMBL5548018 0.85 HSD11B1 (0.53) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5543973 0.82 POLB (0.45) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5543816 0.79 TLR8 (0.33) L3MBTL1ALDH1A1TLR8
SCHEMBL5546084 0.77 HSD11B1 (0.50) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5537170 0.77 ALDH1A1 (0.49) HTTLMNAL3MBTL1ALDH1A1HSD11B1
SCHEMBL25250741 0.76 LMNA (0.54) POLBHTTLMNAL3MBTL1ALDH1A1
SCHEMBL5543115 0.76 POLB (0.52) POLBHTTLMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 POLB 1637/4885HTT 4644/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.